Key Developments: Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

96.83EUR
11:35am EDT
Price Change (% chg)

€-0.49 (-0.50%)
Prev Close
€97.32
Open
€97.90
Day's High
€98.03
Day's Low
€96.78
Volume
1,770,452
Avg. Vol
2,107,699
52-wk High
€104.35
52-wk Low
€77.43

Search Stocks

Latest Key Developments (Source: Significant Developments)

Bayer commences voluntary cash offer to acquire the entire issued share capital of Algeta
Monday, 20 Jan 2014 02:40am EST 

Algeta ASA:Says that Aviator Acquisition AS, a wholly-owned subsidiary of Bayer Nordic SE, has commenced the voluntary cash offer to acquire the entire issued share capital of Algeta for 362 Norwegian crown per share.Says the Offer period starts on Jan. 20 and expires at CET on Feb. 24.  Full Article

Alliance Pharma Plc's subsidiary acquires rights to thyroid product Irenat from subsidiaries of Bayer AG
Tuesday, 14 Jan 2014 02:00am EST 

Alliance Pharma Plc:Says its wholly owned subsidiary Alliance Pharmaceuticals Limited has acquired the rights to the thyroid product Irenat from subsidiaries of Bayer AG.  Full Article

Algeta ASA's Board unanimously recommends voluntary cash offer from Bayer AG to acquire the entire issued share capital of Algeta
Thursday, 19 Dec 2013 02:07am EST 

Algeta ASA:Says an agreement with the Bayer AG (Bayer) whereby Bayer, through Aviator Acquisition AS, a wholly-owned subsidiary of Bayer Nordic SE, will launch a voluntary cash offer (the Offer) to acquire the entire issued share capital of Algeta for 362 norwegian krone per share in cash.Says the offer values the total share capital of Algeta at about 17.6 bln norwegian krone ($2.9 bln) on a fully diluted basis.Says the board of directors of Algeta has unanimously decided to recommend that its shareholders accept the Offer.Says under the terms of the offer, Aviator Acquisition AS will make a voluntary offer to acquire the entire issued share capital of Algeta for 362 per share norwegian krone in cash.Says Bayer will finance the transaction with available cash and new debt.Says Bayer expects to close the transaction during the Q1 2014.Says Goldman Sachs International is acting as exclusive financial advisor to Algeta. Skadden, Arps, Slate, Meagher & Flom LLP and Wikborg, Rein & Co. DA are acting as legal advisors to Algeta.Says Centerview Partners provided an additional fairness opinion in support of the Board of Directors' recommendation of the Offer.  Full Article

Algeta ASA confirms that it is in receipt of preliminary acquisition proposal from Bayer AG
Tuesday, 26 Nov 2013 01:25am EST 

Algeta ASA:Confirms that it is in receipt of a preliminary acquisition proposal from Bayer AG.Says preliminary acquisition proposal is Norwegian Krone 336 per Algeta share.Says no certainty that this preliminary acquisition proposal will lead to a transaction or as to the terms of any such transaction.  Full Article

Bayer AG's Bayer Inc Receives Approval For Eylea As New Drug To Treat Wet Age-Related Macular Degeneration Patients In Canada
Tuesday, 12 Nov 2013 06:59am EST 

Bayer AG's Bayer Inc. announced that it has received approval from Health Canada for Eylea (aflibercept, solution for intravitreal injection) for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD). The Health Canada approval of Eylea is based on the results of two Phase III clinical studies (VIEW 1 and VIEW 2) which demonstrated that aflibercept injection dosed every 8 weeks, following three initial monthly injections, was non-inferior to ranibizumab injection dosed every four weeks. This was measured by the primary endpoint of proportion of subjects who maintained vision. The common adverse reactions (frequency of 5.0% or more) reported in patients receiving aflibercept injection were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and increased intraocular pressure.  Full Article

Bayer AG Sees FY 2013 Revenue Guidance At Low End Of Prior Range; Reaffirms FY 2013 Earnings Guidance-Conference Call
Thursday, 31 Oct 2013 09:00am EDT 

Bayer AG announced that for the group as a whole, it expect sales for fiscal 2013 to increase by currency and portfolio adjusted 4% to 5% to EUR40 billion, and the Company aim to increase EBITDA before special items by a mid-single-digit percentage, and aim to improve core earnings per share (EPS) by a high single-digit percentage. The Company reported EBITDA of EUR8.284 billion and EPS of EUR5.35 in fiscal 2012. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of EUR41 billion, EBITDA of EUR8.472 billion and EPS of EUR5.69 for fiscal 2013.  Full Article

Bayer AG’s Bayer HealthCare Announces US FDA Approval Of Adempas (Riociguat) For Use In Two Forms Of Pulmonary Hypertension
Wednesday, 9 Oct 2013 02:11am EDT 

Bayer AG’s Bayer HealthCare announced that the United States Food and Drug Administration (FDA) has approved Adempas (riociguat) tablets for use in two forms of pulmonary hypertension, a group of life-threatening and progressive diseases: the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class; and the treatment of adults with pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class and delay clinical worsening.  Full Article

Bayer AG’s Bayer HealthCare Receives Recommendation For Approval Of Radium Ra 223 Dichloride For Treatment of Castration-Resistant Prostate Cancer With Bone Metastases In European Union
Friday, 20 Sep 2013 07:49am EDT 

Bayer AG’s Bayer HealthCare announced that the European Committee for Medicinal Products for Human Use (CHMP) recommended radium Ra 223 dichloride (radium-223) for approval with a proposed indication for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. The decision of the European Commission on the approval is expected in the fourth quarter of 2013. Radium-223 was approved by the U.S. Food and Drug Administration (FDA) in May 2013 under the brand name Xofigo.  Full Article

Bayer AB’s Regorafenib Submitted For European Marketing Authorization For Treatment Of Gastrointestinal Stromal Tumors
Thursday, 5 Sep 2013 02:41am EDT 

Bayer AB announced that its unit, Bayer HealthCare, has submitted an application for marketing authorization to the European Medicines Agency (EMA) for the oral multi-kinase inhibitor, regorafenib, for the treatment of patients with gastrointestinal stromal tumors (GlST) who have been previously treated with two tyrosine kinase inhibitors. The EMA filing follows the EU approval of regorafenib (Stivarga) for use in metastatic colorectal cancer in August 2013.  Full Article

Onyx Pharmaceuticals Inc and Bayer's Stivarga (regorafenib) Tablets Approved In Europe
Friday, 30 Aug 2013 02:00am EDT 

Bayer AG's Bayer HealthCare and Onyx Pharmaceuticals, Inc. announced that the European Commission has approved Stivarga (regorafenib) tablets for the treatment of adult patients with metastatic colorectal cancer (mCRC). The approval of Stivarga was based on data from the pivotal Phase III CORRECT (Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) trial.  Full Article

BRIEF-Bayer seeks approval of Riociguat in Japan

FRANKFURT, April 23 - Bayer AG : * Says submits application for approval of riociguat to treat pulmonary

Search Stocks